These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8184873)

  • 21. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of bleeding in dialysis patients.
    Galbusera M; Remuzzi G; Boccardo P
    Semin Dial; 2009; 22(3):279-86. PubMed ID: 19573008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients.
    Malyszko J; Pietraszek M; Buczko W; Mysliwiec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):319-24. PubMed ID: 1697836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of uremic bleeding.
    Couch P; Stumpf JL
    Clin Pharm; 1990 Sep; 9(9):673-81. PubMed ID: 2171866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
    Mannucci PM
    Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
    Mannucci PM; Remuzzi G; Pusineri F; Lombardi R; Valsecchi C; Mecca G; Zimmerman TS
    N Engl J Med; 1983 Jan; 308(1):8-12. PubMed ID: 6401193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacement therapy in platelet-type von Willebrand disease.
    Takahashi H
    Am J Hematol; 1985 Apr; 18(4):351-62. PubMed ID: 3919572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of DDAVP in inherited and acquired platelet dysfunction.
    DiMichele DM; Hathaway WE
    Am J Hematol; 1990 Jan; 33(1):39-45. PubMed ID: 2293761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-arginine, the precursor of nitric oxide, abolishes the effect of estrogens on bleeding time in experimental uremia.
    Zoja C; Noris M; Corna D; Viganò G; Perico N; de Gaetano G; Remuzzi G
    Lab Invest; 1991 Oct; 65(4):479-83. PubMed ID: 1656142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities.
    Blatt PM; Brinkhous KM; Culp HR; Krauss JS; Roberts HR
    JAMA; 1976 Dec; 236(24):2770-2. PubMed ID: 1086910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy.
    Tauer JT; Gneuss A; Lohse JE; Jürgens T; Knöfler R
    Klin Padiatr; 2011 May; 223(3):169-72. PubMed ID: 21509710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor.
    Bovill EG; Ershler WB; Golden EA; Tindle BH; Edson JR
    Am J Clin Pathol; 1986 Jan; 85(1):115-23. PubMed ID: 3079626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assessment of haemostasis in fifteen uraemic patients subjected to chronic haemodialysis (author's transl)].
    Barrantes Boulanger A; Soto Quirós M; Salas González R
    Sangre (Barc); 1980; 25(3):289-99. PubMed ID: 7414445
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effects of substitution hormonal therapy on the hemostasis system in the pathologic climacteric].
    Marchenko LA; Makatsariia AD; Barabanova EV
    Akush Ginekol (Mosk); 1986 May; (5):35-8. PubMed ID: 3017141
    [No Abstract]   [Full Text] [Related]  

  • 39. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
    Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB; Mannucci PM; Lombardi R; Lattuada A; Colibretti ML; Dent JA; Zimmerman TS
    Am J Hematol; 1989 Dec; 32(4):287-93. PubMed ID: 2510503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.